Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
Roivant logo — Reinventing Biopharma

Roivant

Reinventing Biopharma

Founded 2014 United States New York, United States 244 employees Total: $5.01B Biopharma, Biotechnology +2

General Information

Company Name Roivant
Founded Year 2014
Location United States New York, United States
Employees 244
Industries Biopharma, Biotechnology, Health Care +1
Business Model B2B, B2C, Platform
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Roivant. To contact Roivant, visit roivant.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Roivant compare?

A PDF of Roivant and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Roivant soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Roivant

Roivant, with its slogan "Reinventing Biopharma", is a forward-thinking company dedicated to accelerating health improvements by innovating and delivering medicines and technology swiftly to patients. Established in 2014 and headquartered in the United States, the company bridges gaps in the biopharmaceutical sector through its creation of Vants—agile biotech and healthcare technology firms equipped to tackle strategic innovations.

Roivant's development pipeline encompasses a broad spectrum of diseases, including conditions with currently insufficient R&D investment, such as uterine fibroids, endometriosis, prostate cancer, and various pediatric diseases. This strategic focus ensures significant societal impact.

The company's recent financial move, a $411.00M SPAC Private Placement investment closed on 01 October 2021, was led by Montes Archimedes Acquisition Corp. This investment emphasizes Roivant's robust appeal and potential in the dynamic landscape of Biopharma and Healthcare.

Business keywords: Biopharmaceutical Development, Innovative Medicines, Entrepreneurial Biotech, Disease Focused R&D, Uterine Fibroids, Endometriosis, Prostate Cancer, Parkinson’s Disease, Rare Pediatric Conditions, R&D Investment Gap, Technology Deployment, Drug Commercialization, Late-stage Drug Development, Healthcare System Efficiency

Services & Products

Discovery and development of new medicines
Commercialization of pharmaceuticals
Clinical trials management
Establishment of specialized subsidiaries (Vants)

Target Customers

Patients with autoimmune diseases Patients with pulmonary diseases Healthcare professionals Investors interested in biotechnology and pharmaceuticals Regulatory bodies (e.g. FDA)

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Spac Private Placement $411.00M 1
Montes Archimedes Acquisition Corp
01 Oct 2021
Growth Equity VC $200.00M 1
SK Group
SK Group
01 Dec 2020
Merger $3.00B 1
Nippon Investment Company
Nippon Investment Company
01 Sep 2019
Growth Equity VC $200.00M 6
Founders Fund SoftBank Novaquest Capital Management
Founders Fund, SoftBank +4
01 Nov 2018
Growth Equity VC $1.10B 3
Founders Fund SoftBank
Founders Fund, SoftBank +1
01 Aug 2017
Growth Equity VC Undisclosed 1
Viking Global Investors
Viking Global Investors
01 Jul 2016
Growth Equity VC $100.00M 2
Dexcel Pharma QVT Financial LP
Dexcel Pharma, QVT Financial LP
01 May 2014

Roivant Alternatives & Competitors

View All Alternatives
Roivant vs
ACELYRIN, INC.
ACELYRIN, INC. United States

We are a late-stage clinical biopharma company focused on providing life-changing new treatment opti...

Acquired
103 employees
Biopharma, Biotechnology
Compare Roivant vs ACELYRIN, INC.
Roivant vs
Emalex Biosciences
Emalex Biosciences United States

Improving people's lives impacted by central nervous system disorders through meaningful scientific...

Series D
54 employees
Biopharma, Biotechnology
Compare Roivant vs Emalex Biosciences
Roivant vs
Genmab
Genmab Denmark

Differentiated human antibody therapeutics for the treatment of cancer

IPO
2981 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Roivant

Reinventing Biopharma
Roivant was founded in 2014.
Roivant is headquartered in New York, United States.
Roivant operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical Development, Innovative Medicines, Entrepreneurial Biotech and Disease Focused R&D. Its customers include Patients with autoimmune diseases, Patients with pulmonary diseases and Healthcare professionals.
Roivant has a B2B, B2C and Platform business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Roivant has approximately 244 employees.
Roivant has completed 7 funding rounds, raising a total of $5.01B.
Roivant offers: Discovery and development of new medicines, Commercialization of pharmaceuticals, Clinical trials management, Establishment of specialized subsidiaries (Vants).
Top alternatives and competitors to Roivant include ACELYRIN, INC., Emalex Biosciences, Genmab, Lumos Pharma, Spero Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Roivant and ACELYRIN, INC. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Roivant, https://bouncewatch.com/company/roivant-sciences, updated 6 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout